Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 32Myelodysplastic Syndromes 16Leukemia, Myelomonocytic, Chronic 7Recurrence 6Neoplasms 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia 3Leukemia, Myeloid 2Carcinoma, Non-Small-Cell Lung 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Preleukemia 1Polycythemia Vera 1Pathologic Complete Response 1Myeloproliferative Disorders 1Melanoma 1Malignant Solid Tumor 1Hematologic Diseases 1Carcinoma, Renal Cell 1Bone Marrow Diseases 1Blast Crisis 1Advanced Breast Cancer 1

Interventions

Imatinib Mesylate 5ruxolitinib 4ponatinib 4nilotinib 4Azacitidine 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2spartalizumab 1sonidegib 1simtuzumab 1sabatolimab 1bosutinib 1Zoledronic Acid 1SCIO-469 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Denosumab 1Decitabine 1CPI-0610 1BID protein, human 14-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Bone Marrow Diseases × Decitabine × Clear all
NCT03066648 2025-05-18

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Novartis

Phase 1 Completed
241 enrolled
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡